

Ankylosing Spondylitis Drugs Market Growth, Global Survey, Analysis, Share, Company Profiles and Forecast by 2027

The rise in the incidence rate of ankylosing spondylitis, the elevating focus on R&D activities, and lack of approval of therapies have resulted

NEW YORK, NEW YORK, UNITED STATES, September 22, 2021 /EINPresswire.com/ -- The global ankylosing spondylitis drugs market is forecast to reach USD 8.82 Billion by



2027, according to a new report by Reports and Data. Ankylosing spondylitis (AS) is a chronic condition that has no permanent cure. It can be defined as an inflammatory disease that results in some of the small bones in the spine (vertebrae) to fuse over time. The fusing of the small bones results in making the spine less flexible and can haunch it in a forward position. In case it affects the rib cage, the patient can have an issue with breathing deeply. The condition effects more men as compared to women. Symptoms and signs associated with condition usually initiates in adulthood. Inflammation associated with the condition may also occur in other parts of the body like eyes. Early signs associated with condition may include stiffness and pain in the lower back and hips, particularly in the morning and after prolonged sitting. Fatigue and neck pain are also common in AS. Though there is no cure to the condition with effective medication and treatment, the symptom can be managed and controlled. Various types of medications may help in stopping or delaying spinal problems and ease the pain & swelling. In regards to region, Europe, can be seen to occupy a prominent market share. The market position held by the region is attributed to high prevalence rate of the condition in this region, along with continuously expanding healthcare sector.

Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/2427

Key participants include

Merck & Co., Boehringer Ingelheim, UCB, Amgen, Janssen Biotech, Inc., Johnson & Johnson, Abbvie, Hetero, Zydus Cadila, and Izana Bioscience.

The global Ankylosing Spondylitis Drugs market is expected to register significant growth throughout the forecast period. The pharmaceutical & healthcare sector has register significant revenue growth over the recent past. Technological advancements in the healthcare and medical sector, availability of latest tools and techniques, increasing investments in the healthcare sector and improving healthcare infrastructure are key factors boosting market growth. In addition, rising funds by several public and private sectors, high adoption of POC diagnosis and home care settings, is further fueling market growth.

The current pandemic has been very challenging for all industries including the healthcare and pharma sector. Shortage of medicines, vaccines and others healthcare facilities is expected to open lucrative growth opportunities for market players in going ahead.

Competitive Landscape:

The report offers detailed information about recent activities by market players, their market position, financial status, global standing, services and product portfolio along with license agreement. These key players are adopting various strategies such as partnerships, collaborations, merger and acquisitions, and joint ventures to gain robust footing in the market. These players are also investing in research and development activities to come up with enhanced materials and products.

Further key findings from the report suggest

- The Ankylosing Spondylitis Drugs market held a market value of USD 5.60 Billion in the year 2018 that is forecasted to grow at a rate of 5.1% during the forecast period.
- In context to Drug Type, the Nonsteroidal Anti-Inflammatory Drugs segment generated the highest revenue of USD 2.58 Billion in 2018, with a CAGR of 5.3% during the forecast period. Its effectiveness in minimizing inflammation, which is a major impact of the diseases and the main goal of the care services, results in a high demand for Nonsteroidal Anti-Inflammatory Drugs among care providers that contributes to the revenue generated by this segment.
- In context to Route of Administration, the Parenteral segment is projected to witness a faster growth rate of 4.3% during the forecast period, which is expected to occupy 35.0% of the market by 2027. The growth rate witnessed by the segment is attributed to the presence of strong pipeline products and continuous development in biologics that are needed to be administered in this way. The fact that medications, when administered in the form of injectable, works the specific problem area and given prompt result, have resulted in its growing popularity care providers.
- In context to Distribution Channel, the Online Pharmacy segment is projected to witness the fastest growth rate of 5.8% during the forecast period, which is expected to occupy 26.5% by 2027. The growth of online medicine shops, rising trend of online purchase of medicine due to

benefits like comfort, convenience, and various offers in these shops contributes to the growth rate witnessed by this segment.

- In regards to Application, the Adults segment generated a higher revenue of USD 4.09 Billion in 2018, with a CAGR of 5.5% during the forecast period. The fact that the signs associated with the condition usually initiates in adulthood and appears prior to the age of 45 results in higher application of these medications among adults.
- In regards to the region, Asia Pacific is projected to witness the fastest growth rate of 5.7% during the forecast, which is expected to hold 0% of the market by 2027. The growth rate witnessed by the region is resultant of the expansion of the health care sector, and increasing focus on R&D activities, which is supporting the market growth in this region.

Request a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/2427

For the purpose of this report, Reports and Data have segmented the global Ankylosing Spondylitis Drugs market, according to Drug Type, Route of Administration, Distribution Channel, Application and Region:

Drug Type Outlook (Revenue, USD Billion; 2016-2027)

- · Nonsteroidal Anti-Inflammatory Drugs
- Anti-Inflammatory Drugs
- Immunosuppressive Drugs
- TNF blockers
- JAK Inhibitors
- Steroids
- Biologics
- Others

Route of Administration Outlook (Revenue, USD Billion; 2016-2027)

- Parenteral
- Oral

Distribution Channel Outlook (Revenue, USD Billion; 2016-2027)

- Hospitals Pharmacy
- Retail Pharmacy
- Online Pharmacy

Application Outlook (Revenue, USD Billion; 2016-2027)

- Adults
- Juveniles

Key Regional Markets:

- North America
- Europe
- · Asia Pacific
- Latin America
- Middle East & Africa

Key findings in the report:

- Information about key trends, technological developments, growing focus on drug discovery and investments in research and development activities
- Detailed insights about manufactures, product portfolios, pricing analysis and financial pricing
- Technological developments and detailed analysis in the volatile competitive landscape.
- New strategies adopted by new and emerging market players
- Estimation about manufactures, sales and import and export dynamics

Request a customization of the report @ https://www.reportsanddata.com/request-customization-form/2427

Thank you for reading the research report on global Ankylosing Spondylitis Drugs market. Kindly contact us to know more about the customization feature and our team will offer the best suited report as per your requirement.

Read More Reports:-

Blood Group Typing Market @

https://www.google.de/url?q=https://www.reportsanddata.com/report-detail/blood-group-typing-market

Creatinine Measurement Market @

https://www.google.com.tr/url?q=https://www.reportsanddata.com/report-detail/creatinine-measurement-market

Hematologic Malignancies Market @

https://www.google.com.ua/url?q=https://www.reportsanddata.com/report-detail/hematologic-malignancies-market

Neglected Tropical Diseases Diagnosis Market @

https://www.google.cl/url?q=https://www.reportsanddata.com/report-detail/neglected-tropical-diseases-diagnosis-market

Homogenizers Market @ https://www.reportsanddata.com/report-detail/homogenizers-market

About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client's make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.

Tushar Rajput
Reports and Data
+ + 12127101370
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/552037520

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.